ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022
Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Navigating the landscape of liver transplantation in neuroendocrine tumors: A comprehensive scoping review.World journal of transplantation · 2026Article
- Surgical Approach to Liver Metastasis from Gastroenteropancreatic Neuroendocrine Tumors in the Era of Precision Oncology.Cancers · 2026Review
- Surgical management of small intestinal neuroendocrine tumours.The British journal of surgery · 2026Article
- Should We Continue Liver Transplantation in Spain for Hepatic Metastases from Neuroendocrine Tumors?Journal of clinical medicine · 2026Article
- Primary and secondary metastatic dissemination: multiple routes to cancer-related death.Molecular cancer · 2025Review
- Article
- Article
- Liver transplantation for the treatment of neuroendocrine liver metastases.Frontiers in surgery · 2025Review
- Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.Journal of gastroenterology · 2025Review
- Liver Transplantation for the Cure of Neuroendocrine Liver Metastasis: A Systematic Review with Particular Attention to the Risk Factors of Death and Recurrence.Biomedicines · 2024Review
- Current Management of Neuroendocrine Tumour Liver Metastases.Current oncology reports · 2024Review
- Evolution of Liver Transplantation Indications: Expanding Horizons.Medicina (Kaunas, Lithuania) · 2024Review
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence.JHEP reports : innovation in hepatology · 2023Review
- The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Current treatment options in oncology · 2023Review
- Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Review
- Liver transplantation in gastroenteropancreatic neuroendocrine tumors.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver resection (LR) is considered the treatment of choice for resectable neuroendocrine liver metastases (NELM), while liver transplantation (LT) is currently reserved for highly selected unresectable patients. We retrospectively analyzed data from consecutive patients undergoing either curative resection or transplantation for liver-only NELM meeting Milan criteria at a single center between 1984 and 2019. Patients who fit Milan criteria were 48 in the transplantation group and 56 in the resection group. After a median follow-up of 158 months for the transplantation group and 126 for the resection group, the 10-year survival rate was 93% for transplantation and 75% for resection (p = .007). The 10-year disease-free survival rate was 52% for transplantation and 18% for resection (p < .001). Transplantation was associated with improved survival at univariate analysis. The median disease-free interval between surgery and recurrence was 78 months for transplantation vs. 24 months for resection (p < .001). The transplantation group had more multisite recurrences (12/25, 48% vs. 5/42, 12% in the resection group, p = .001), while most recurrences in the resection group were intra-hepatic (37/42, 88%, versus 2/25, 8% in the transplantation group). In conclusion, LT was associated with improved survival outcomes in NELM meeting the Milan criteria compared with LR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.